

EBMT Centre Identification Code (CIC): ____

Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry:	
ACUTE L	EUKAEMIAS
DIS	SEASE
Consult the manual for further information. Pate of diagnosis://(YYYY/MM/DD) Classification: Acute myeloid leukaemia (AML) Precursor lymphoid neoplasm (ALL) Other acute leukaemia	dication for a HCT/CT/GT or if it was specifically requested.
Haemato	logical values
Peripheral blood	
White Blood cell count (109/L):	☐ Not evaluated ☐ Unknown
% blasts :	☐ Not evaluated ☐ Unknown
Bone marrow	
% blasts :	☐ Not evaluated ☐ Unknown

Treatment Type HCT CT GT IST Other



EBMT H	BMT Centre Identification Code (CIC): _ ospital Unique Patient Number (UPN): _ atient Number in EBMT Registry:			e	GT IST Other
	Acute Mye	loid Leukaem	nias (AML	.)	
		DISEASE			
Classification:					
	ysplasia related changes?				
∏ No	, ,				
_	there a previous diagnosis of MDS	, MPN or MDS/MPI	N? No		
☐ Unknown			☐ Yes	(complete the respe form in addition to the	-
	nyeloid neoplasia (old "secondary a	cute leukaemia")?			
•	eatment but not after a previous MPN or MDS/MPN	□ No)		
		☐ Ye		the respective diagno the current form)	sis form in
		☐ Ur	nknown		
	CHRC	DMOSOME ANAL	YSIS		
	nalysis done at diagnosis: of the analysis at time of diagnosis)				
☐ No ☐ Yes: ☐ Unknown	Output of analysis: Separate	abnormalities [] Full karyoty	pe	
If chromosome	e analysis was done:				
Date of chron	nosome analysis:ll	(YYYY/MM/DD) 🗀	Unknown		
What were th	e results?				
☐ Normal					
☐ Abnormal:	Number of abnormalities present	t:			
	Complex karyotype:	☐ No ☐ Yes ☐	Unknown		
	Monosomal karyotype: (≥2 autosomal monosomies or 1 autosomal monosomy + at least 1 structural abnormality)	□ No □ Yes □	Unknown		
	Multiple trisomies:	☐ No ☐ Yes ☐	Unknown		
☐ Failed					



EBMT Centre Identification Code (CIC):	Treatment Type HCT CT GT IST Other
Hospital Unique Patient Number (UPN):	
Patient Number in EBMT Registry:	Treatment Date / (YYYY/MM/DD)

CHROMOSOME ANALYSIS continued

For abnormal results, indicate below whether the abnormalities were absent, present or not evaluated.

t(15;17)	☐ Absent ☐ Present ☐ Not evaluated
t(8;21)	☐ Absent ☐ Present ☐ Not evaluated
inv(16)/ t(16;16)	☐ Absent ☐ Present ☐ Not evaluated
11q23 abnormality type, if a 11q23 abnormality is present:	☐ Absent ☐ Present ☐ Not evaluated
t(9;11)	☐ Absent ☐ Present ☐ Not evaluated
t(11;19)	☐ Absent ☐ Present ☐ Not evaluated
t(10;11)	☐ Absent ☐ Present ☐ Not evaluated
t(6;11)	☐ Absent ☐ Present ☐ Not evaluated
Other abn(11q23); specify:	☐ Absent ☐ Present
3q26 (EVI1) abnormality type, if a 3q26 abnormality is present:	☐ Absent ☐ Present ☐ Not evaluated
inv(3) / t(3;3)	☐ Absent ☐ Present ☐ Not evaluated
t(2;3)(p21;q26)	☐ Absent ☐ Present ☐ Not evaluated
Other (3q26)/EVI1 rearrangement; specify:	☐ Absent ☐ Present
t(6;9)	☐ Absent ☐ Present ☐ Not evaluated
abn 5 type, if an abn 5 is present:	☐ Absent ☐ Present ☐ Not evaluated
del (5q)	☐ Absent ☐ Present ☐ Not evaluated
monosomy 5	☐ Absent ☐ Present ☐ Not evaluated
add(5q)	☐ Absent ☐ Present ☐ Not evaluated
Other abn(5q); specify:	☐ Absent ☐ Present
abn 7 type, if an abn 7 is present:	☐ Absent ☐ Present ☐ Not evaluated
del(7q)	☐ Absent ☐ Present ☐ Not evaluated
monosomy 7	☐ Absent ☐ Present ☐ Not evaluated
add(7q)	☐ Absent ☐ Present ☐ Not evaluated
Other abn(7q); specify:	☐ Absent ☐ Present
Monosomy 17	☐ Absent ☐ Present ☐ Not evaluated
abn(17p)	☐ Absent ☐ Present ☐ Not evaluated
t(1;22)	☐ Absent ☐ Present ☐ Not evaluated
Trisomy 8	☐ Absent ☐ Present ☐ Not evaluated
t(9;22)	Absent Present Not evaluated
t(8;16)	☐ Absent ☐ Present ☐ Not evaluated
Other; specify:	Absent Present
OR	

Transcribe the complete karyotype: _____



	MOLECULAR MARKER	ANALYSIS
ΔT	Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry:	Treatment Date / (YYYY/MM/DD)
AT	EBMT Centre Identification Code (CIC):	Treatment Type HCT CT GT IST Other

Molecular marker analysis at diagnosis: No ☐ Yes: Date of molecular marker analysis: _ _ _ / _ _ (YYYY/MM/DD) ☐ Unknown ☐ Unknown Indicate below whether the markers were absent, present or not evaluated. AML1-ETO (RUNX1/RUNXT1) Present ■ Not evaluated ☐ Absent Molecular product of t(8;21) CBFB-MYH11 Present ☐ Not evaluated ☐ Absent Molecular product of inv(16)(p13.1;q22) or (16;16)(p13.1;q22) PML-RARα Present Not evaluated Absent Molecular product of t(15;17) MLL (KMT2A)-rearrangement/mutation: Absent Present ☐ Not evaluated MLLT3(AF9)-MLL Absent Present ☐ Not evaluated Molecular product of t(9;11)(p22;q23) **MLL-PTD** Present ☐ Not evaluated Absent (partial tandem duplication) MLLT4(AF6)-MLL ■ Not evaluated Absent Present Molecular product of t(6;11)(q27;q23) ☐ Absent Present ☐ Not evaluated Molecular product of t(11;19)(q23;p13.1) MLLT1(ENL)-MLL ☐ Not evaluated Absent Present Molecular product of t(11;19)(q23;p13.3) MLLT10(AF10)-MLL ☐ Not evaluated ☐ Absent Present Molecular product of t(10;11)(p12;q23) Other MLL-rearrangement; specify: Absent Present **DEK-NUP214(CAN)** ☐ Absent Present ☐ Not evaluated Molecular product of translocation t(6;9)(p23;q34) RPN1-EVI1 ■ Not evaluated Absent Present Molecular product of inv(3)(q21q26.2) or t(3;3)(q21q26.2) RBM15-MKL1 ☐ Absent Present ☐ Not evaluated Molecular product of translocation t(1;22)(p13;q13)NPM1 Absent Present ☐ Not evaluated c-KIT ☐ Not evaluated □ Absent Present **DNMT3A** ☐ Not evaluated Absent Present ASXL1 ☐ Not evaluated □ Absent Present TP53 ☐ Not evaluated ☐ Absent Present **RUNX1** □ Absent Present ☐ Not evaluated IDH1 Present ☐ Not evaluated ☐ Absent IDH2 Present ☐ Not evaluated ☐ Absent **BRAT** Present ☐ Not evaluated Absent SRSF2 ☐ Absent Present ☐ Not evaluated SF3B1 Absent Present **CEBPA** ☐ Present ☐ Not evaluated ☐ Absent if CEBPA present: bZIP mutation: No Yes Unknown □ No ☐ Yes ☐ Unknown biallelic: Absent Present FLT3-ITD (internal tandem duplication) FLT3-TKD Absent ☐ Not evaluated Present



EBMT Centre Identification Code (CIC):	Treatment Type HCT CT GT IST Other
Hospital Unique Patient Number (UPN):	
Patient Number in EBMT Registry:	Treatment Date / / (YYYY/MM/DD)

MOLECULAR MARKER ANALYSIS continued

Indicate below whether the markers were absent, present or not evaluated.	
•	

BCR-ABL	Absent	Present	☐ Not evaluated
GATA2	Absent	Present	☐ Not evaluated
MECOM(EVI1)	Absent	Present	☐ Not evaluated
KAT6A-CREBBP	Absent	Present	☐ Not evaluated
BCOR	Absent	Present	☐ Not evaluated
EZH2	Absent	Present	☐ Not evaluated
STAG2	Absent	Present	□ Not evaluated
U2AF1	Absent	Present	☐ Not evaluated
ZRSR2	Absent	Present	☐ Not evaluated
Other; specify:	Absent	Present	

Next Generation Sequencing (NGS) performed at diagnosis:	☐ No
	☐ Yes
	☐ Unknown



EBMT		on Code (CIC): lumber (UPN): Registry:		□ c
		DIS	SEASE	
Other AML of	classification:			
☐ Acute pa	ınmyelosis with myelofibr	rosis		
☐ Myeloid :	sarcoma (granulocytic sa	rcoma)		
☐ Myeloid ¡	proliferations related to D	own syndrome		
☐ Blastic p	lasmacytoid dendritic cel	l neoplasm (BPDCN)		
AML with AML with Acute pr Acute m Acute m Acute er Acute m	rication: In minimal differentiation (Fabruary) In maturation (FAB M1) In maturation (FAB M2) In maturation (FAB M	AB M3) (FAB M4) Ieukaemia (FAB M5)	□ Unknown	
	edullary involvement:		_	
	olved at time of diagno	Yes No sis: Yes Yes Yes	☐ Unknown☐ Not evaluated☐ Not evaluated	
Testes/Ovar	<u> </u>	☐ Yes	☐ Not evaluated	
Other; spec	ify:	☐ Yes		



☐ Normal ☐ Abnormal:

☐ Failed

Acute_Leukaemias_v2.0

ЕВМТ	EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry:	Treatment Type HCT CT GT IST Other Treatment Date// (YYYY/MM/DD)
	Precursor Lymphoid Ne	oplasms (previously ALL)
	DISE	EASE
Classificati	on:	
☐ B lympho	oblastic leukaemia/lymphoma	
☐ T lympho	blastic leukaemia/lymphoma	
Other pre	ecursor lymphoid neoplasm; specify:	
] No] Yes: (If no	rigin: is this PLN related to prior exposure to the ot reported yet, complete respective non-indication te to exposure to: Chemotherapy / radiotherapy treated disease multiple immune suppression Other; specify Unknown	n diagnosis form in addition to the current form)
	CHROMOSON	ME ANALYSIS
	ne analysis done at diagnosis: sults of the analysis at time of diagnosis)	
☐ No ☐ Yes: ☐ Unkno	Output of analysis: Separate abnormalition	es Full karyotype
If chromos	some analysis was done:	
Date of cl	hromosome analysis: I I (YYYY/M	<i>IM/DD</i>) ☐ Unknown
What wei	re the results?	

7 of 12

2024-06-04

Number of abnormalities present: $_$

Complex karyotype: No Yes Unknown



EBMT Centre Identification Code (CIC):	Treatment Type HCT CT GT IST Other
Hospital Unique Patient Number (UPN):	
Patient Number in EBMT Registry:	Treatment Date / _ / _ (YYYY/MM/DD)

CHROMOSOME ANALYSIS continued

For abnormal results, indicate below whether the abnormalities were absent, present or not evaluated.

t(9;22)	Absent	☐ Present	☐ Not evaluated
11q23 abnormalities (fill in only if 11q23 abnormality is present):	Absent	☐ Present	☐ Not evaluated
t(4;11)	Absent	Present	☐ Not evaluated
Other abn(11q23); specify:	☐ Absent	☐ Present	
t(12;21)	Absent	Present	☐ Not evaluated
Hyperdiploidy > 46 chromosomes (fill in only if hyperdiploidy is present):	☐ Absent	☐ Present	☐ Not evaluated
51-67 chromosomes	Absent	Present	☐ Not evaluated
Trisomy; specify extra chromosome:	☐ Absent	☐ Present	☐ Not evaluated
Other hyperdiploid karyotype; number of chromosomes:	Absent	Present	
Hypodiploidy < 46 chromosomes (fill in only if hypodiploidy is present):	Absent	☐ Present	☐ Not evaluated
Low hypodiploid: 32 - 39 chromosomes	☐ Absent	☐ Present	☐ Not evaluated
Near haploid: 24-31 chromosomes	☐ Absent	☐ Present	☐ Not evaluated
Monosomy; specify:	☐ Absent	☐ Present	☐ Not Evaluated
Other; number of chromosomes:	☐ Absent	☐ Present	
iAMP21 (intrachromosomal amplification of chromosome 21)	☐ Absent	Present	☐ Not evaluated
t(5;14)(q31;q32)	☐ Absent	☐ Present	☐ Not evaluated
t(1;19)	☐ Absent	☐ Present	☐ Not evaluated
Trisomy 8	Absent	☐ Present	☐ Not Evaluated
Other; specify:	☐ Absent	☐ Present	
OR			
Transcribe the complete karyotyne:			



EBMT Centre Identification Code (CIC):	Treatment Type HCT CT GT IST Other
Hospital Unique Patient Number (UPN):	
Patient Number in EBMT Registry:	Treatment Date / (YYYY/MM/DD)

MOLECULAR MARKER ANALYSIS

Molecular marker analysis at diagnosis:				
□ No				
Yes; Date of molecular marker analysis: / / (YYYY/MM/DD) Unknown				
Unknown				
ndicate below whether the abnormalities were absent, present or no	ot evaluated.			
BCR-ABL Molecular product of t(9;22)(q34;q11.2)	☐ Absent	☐ Present ☐ Not evaluated		
PML-RARα Molecular product of t(15;17)	☐ Absent	☐ Present ☐ Not evaluated		
MLL (KMT2A)-rearrangement/mutation:	Absent	Present Not evaluated		
AFF1(AF4)-MLL <i>M</i> Molecular product of t(4;11)(q21;q23)	☐ Absent	☐ Present ☐ Not evaluated		
MLLT1(ENL)-MLL Molecular product of t(11;19)(q23;p13.3)	Absent	☐ Present ☐ Not evaluated		
MLLT3(AF9)-MLL Molecular product of t(9;11)(p22;q23)	☐ Absent	☐ Present ☐ Not evaluated		
Other MLL-rearrangement; specify:	Absent	☐ Present		
TEL(ETV6)-AML1(RUNX1) Molecular product of t(12;21)(p13;q22)	Absent	☐ Present ☐ Not evaluated		
IL3-IGH Molecular product of translocation t(5;14)(q31;q32)	Absent	☐ Present ☐ Not evaluated		
TCF3-PBX1 Molecular product of translocation (1;19)(q23;p13.3)	Absent	☐ Present ☐ Not evaluated		
IKZF1 (IKAROS)	Absent	Present Not evaluated		
NOTCH1 / FBWX7	☐ Absent	☐ Present ☐ Not evaluated		
PAX5	☐ Absent	☐ Present ☐ Not evaluated		
KRAS	☐ Absent	☐ Present ☐ Not evaluated		
NRAS	Absent	☐ Present ☐ Not evaluated		
PTEN	☐ Absent	☐ Present ☐ Not evaluated		
FLT3	☐ Absent	☐ Present ☐ Not evaluated		
PTPN11	☐ Absent	☐ Present ☐ Not evaluated		
BCL/MYC-rearranged	☐ Absent	Present Not evaluated		
Other; specify:	☐ Absent	☐ Present		



EBMT Centre Identification Code (CIC):	Treatment Type HCT CT GT IST Other
Hospital Unique Patient Number (UPN):	
Patient Number in EBMT Registry:	Treatment Date // (YYYY/MM/DD)

MOLECULAR MARKER ANALYSIS continued

Ph-like ALL?				
☐ No (skip the table below)				
Yes (complete the table below)				
☐ Not evaluated				
CRFL2-P2RY8	☐ Absent ☐ Present ☐ Not evaluated			
Other CRFL2 rearrangement; specify:	☐ Absent ☐ Present			
ABL1 rearrangement:	☐ Absent ☐ Present ☐ Not evaluated			
ABL1-ETV6	☐ Absent ☐ Present ☐ Not evaluated			
ABL1-NUP214	☐ Absent ☐ Present ☐ Not evaluated			
Other ABL1 rearrangement; specify:	☐ Absent ☐ Present			
ABL2 rearrangement:	☐ Absent ☐ Present ☐ Not evaluated			
ABL2-RCSD1	☐ Absent ☐ Present ☐ Not evaluated			
Other ABL2 rearrangement; specify:	Absent Present			
JAK2 rearrangement:	☐ Absent ☐ Present ☐ Not evaluated			
JAK2-PAX5	☐ Absent ☐ Present ☐ Not evaluated			
JAK2-BCR	Absent Present Not evaluated			
Other JAK2 rearrangement; specify:	Absent Present			
EPOR rearrangement:	☐ Absent ☐ Present ☐ Not evaluated			
EPOR-IGH	Absent Present Not evaluated			
Other EPOR rearrangement; specify:	Absent Present			
Next Generation Sequencing (NGS) performed at diagnosis: No Yes Unknown				
DISEASE				
Involvement at time of diagnosis: Medullary involvement: Yes No Extramedullary involvement: Yes No	☐ Unknown			
Organs involved at time of diagnosis:				
Skin: No Yes	☐ Not evaluated			
CNS: No Yes	☐ Not evaluated			
Testes/Ovaries: No Yes	☐ Not evaluated			
Other; specify: No Yes				



EBMT +	Treatment Type HCT CT GT IST Other Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry: Treatment Date/_/ (YYYY/MM/DD)
	Other Acute Leukaemias
	DISEASE
Classification: Acute leukaemi	as of ambiguous lineage
	erentiated leukaemia
	otype (B, T, NOS)
<u> </u>	(NK) - cell lymphoblastic leukaemia/lymphoma
Other; speci	y:
Secondary orig	gin: is this other acute leukaemia related to prior exposure to therapeutic drugs or radiation?
Yes: (If not	reported yet, complete respective non-indication diagnosis form in addition to the current form)
Due	to exposure to: Chemotherapy / radiotherapy
	☐ Immune suppression
	Other; specify
☐ Unknown	Unknown
	CHROMOSOME ANALYSIS
Chromosome a	nalysis done at diagnosis:
	of the analysis at time of diagnosis)
☐ No	
Yes:	Output of analysis: Separate abnormalities Full karyotype
☐ Unknown	
If chromosom	e analysis was done:
Date of chror	mosome analysis: I (YYYY/MM/DD)
What were th	ne results?
☐ Normal	
Abnormal:	•
	Complex karyotype: No Yes Unknown
	Chromosomal abnormalities; specify:
	OR
	Transcribe the complete karyotype:
☐ Failed	



EBMT	EBMT Centre Identificati Hospital Unique Patient Patient Number in EBM ⁻	Number (UPN)):	
DISEASE				
Involvement at time of diagnosis:				
Medull	lary involvement:	☐ Yes	☐ No	Unknown
Extran	nedullary involvement:	☐ Yes	□ No	Unknown
Organs involved at time of diagnosis:				
Skin:	□ N	lo [] Yes	☐ Not evaluated
CNS:		lo [] Yes	☐ Not evaluated
Testes/Ova	aries 🔲 N	10 [] Yes	☐ Not evaluated
Other; spe	cify: \ \	10 [] Yes	